Covered recipient · General Payments record
BHUMIKA JAYANTIBHAI PATEL
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$194,388.50
- Reported across 250 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $19,169.75 | 6 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,888.00 | 2 |
| Travel and Lodging | $2,305.12 | 7 |
| Food and Beverage | $1,446.19 | 38 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Alexion Pharmaceuticals, Inc. | $14,885.51 | 14 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $9,689.08 | 12 |
| Apellis Pharmaceuticals, Inc. | $2,282.50 | 1 |
| E.R. Squibb & Sons, L.L.C. | $346.00 | 1 |
| Amgen Inc. | $117.82 | 1 |
| Daiichi Sankyo Inc. | $81.89 | 4 |
| BOSTON SCIENTIFIC CORPORATION | $50.64 | 1 |
| Astellas Pharma US Inc | $39.80 | 2 |
| Stemline Therapeutics Inc. | $39.31 | 2 |
| PFIZER INC. | $34.76 | 2 |
| Ipsen Biopharmaceuticals, Inc | $26.94 | 1 |
| ABBVIE INC. | $26.79 | 1 |
| Janssen Biotech, Inc. | $24.06 | 1 |
| Fennec Pharmaceuticals, Inc. | $20.81 | 1 |
| TAIHO ONCOLOGY, INC. | $18.64 | 1 |
| Acrotech Biopharma Inc. | $18.63 | 1 |
| BeiGene USA, Inc. | $17.76 | 1 |
| Rigel Pharmaceuticals, Inc. | $17.60 | 1 |
| Incyte Corporation | $16.48 | 1 |
| Acerta Pharma LLC | $14.33 | 1 |
| Geron Corporation | $13.31 | 1 |
| Adaptive Biotechnologies Corporation | $13.21 | 1 |
| Exelixis Inc. | $13.19 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (53)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.